Health
Dexamethasone use could reduce immune checkpoint inhibitor efficacy in glioblastoma patients – News-Medical.Net
Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral…
Reviewed by Emily Henderson, B.Sc.Nov 25 2020
Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival.
Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research
Author: David A. Reardon, MD, clinical director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute in…
-
Noosa News18 hours agoThe Laundry Lady secures $1M to fuel international expansion
-
General22 hours agoEveryday AI use brings a hidden climate cost
-
Noosa News14 hours agoTruffle growers say rare delicacy is worth its $3,500 per kilo expense
-
Business18 hours agoHow did the market react to this dividend stock’s earnings results?